Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
75% of people treated with a combination of immunotherapy, targeted therapy and chemotherapy saw their tumors shrink.
New checkpoint inhibitor Jemperli is approved for cancers with deficient mismatch repair mechanism for fixing damaged DNA.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
The Nobel Prize winner continues to search for more immune checkpoints that can be blocked.
Study participants who received Libtayo had a 31% lower risk of death than those treated with chemotherapy.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
Opdivo plus Cabometyx reduced the risk of death by 40%.
The checkpoint inhibitor delayed disease progression and improved overall survival in non-small-cell lung cancer patients.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from cancer immunotherapies.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
About a quarter of patients with advanced skin cancer experienced tumor shrinkage in a clinical trial.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.